NeurogesX Reports Third Quarter 2012 Results
November 14, 2012 16:10 ET
|
NeurogesX
Recent Highlights:
End-of-Phase 2 FDA interaction sets guidance to enable initiation of NGX-1998 Phase 3 studies
Presented NGX-1998 Phase 2 trial data at World Congress; showed clear dose...
NeurogesX to Present at Rodman & Renshaw 14th Annual Healthcare Conference
September 05, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
NeurogesX' NGX-1998 Well-Tolerated Treatment Demonstrated Clear Dose-Response in Patients
August 30, 2012 11:00 ET
|
NeurogesX
NGX-1998 Phase 2 Study Data Presented at World Congress on Pain
Multiple Posters on Qutenza® Presented by Partner Astellas
SAN MATEO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- NeurogesX,...
NeurogesX to Present at Wedbush PacGrow 2012 Life Sciences Management Access Conference
August 09, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
NeurogesX Provides Regulatory Update for NGX-1998 Clinical Program
August 07, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Aug. 7, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
NeurogesX Reports Second Quarter 2012 Results
August 03, 2012 08:00 ET
|
NeurogesX
Q2 2012 and Recent Highlights:
Business development process proceeding for NGX-1998 and Qutenza
End-of-Phase 2 meeting package submitted and accepted by FDA
Astellas enrolled first...
NeurogesX Receives Additional Notice of Allowance Covering NGX-1998 in U.S.
August 02, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Aug. 2, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
NeurogesX to Hold Conference Call to Discuss Second Quarter 2012 Results
July 27, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., July 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...
NeurogesX Partner Astellas Enrolls First Patient in EU Clinical Trial for QUTENZA(R) (8% capsaicin patch)
July 24, 2012 03:00 ET
|
NeurogesX
Head-to-Head Study Will Compare Qutenza and Pregabalin in the Treatment of Peripheral Neuropathic Pain
ELEVATE Study First to Compare Efficacy, Tolerability and Impact on Quality of Life Versus...
NeurogesX NGX-1998 Phase 2 Study Data to be Presented at World Congress on Pain
July 16, 2012 12:00 ET
|
NeurogesX
SAN MATEO, Calif., July 16, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel...